(MedPage Today) — The FDA approved a pill version of the GLP-1 receptor agonist semaglutide (Wegovy), making it the first oral GLP-1 agent indicated for weight loss, Novo Nordisk announced on Monday.
The once-daily 25 mg pill is approved to lower…
Source link : https://www.medpagetoday.com/endocrinology/obesity/119154
Author :
Publish date : 2025-12-23 14:25:00
Copyright for syndicated content belongs to the linked Source.
